MX2021009971A - Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. - Google Patents
Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.Info
- Publication number
- MX2021009971A MX2021009971A MX2021009971A MX2021009971A MX2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A MX 2021009971 A MX2021009971 A MX 2021009971A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- pharmaceutical composition
- heterocyclic compound
- same
- method therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910124584 | 2019-02-19 | ||
| CN201910437878 | 2019-05-24 | ||
| CN201910932095 | 2019-09-29 | ||
| PCT/CN2020/074696 WO2020168939A1 (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009971A true MX2021009971A (es) | 2021-10-13 |
Family
ID=72143544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009971A MX2021009971A (es) | 2019-02-19 | 2020-02-11 | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220144847A1 (enExample) |
| EP (1) | EP3929198A4 (enExample) |
| JP (2) | JP7615056B2 (enExample) |
| KR (1) | KR102977603B1 (enExample) |
| CN (3) | CN117327078A (enExample) |
| AU (1) | AU2020226422C1 (enExample) |
| BR (1) | BR112021016299A2 (enExample) |
| CA (1) | CA3130245A1 (enExample) |
| CL (1) | CL2021002205A1 (enExample) |
| CO (1) | CO2021011023A2 (enExample) |
| IL (1) | IL285378B2 (enExample) |
| MX (1) | MX2021009971A (enExample) |
| PH (1) | PH12021552004A1 (enExample) |
| SA (1) | SA521430084B1 (enExample) |
| SG (1) | SG11202107848TA (enExample) |
| WO (1) | WO2020168939A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7688690B2 (ja) * | 2020-07-28 | 2025-06-04 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | ピリミジン系化合物の塩、結晶形およびその調製方法 |
| WO2022199503A1 (zh) | 2021-03-24 | 2022-09-29 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 |
| CN114235976B (zh) * | 2021-11-09 | 2023-11-03 | 暨南大学 | 一种含氮杂环有机化合物中间产物的合成和分析方法 |
| CN120897743A (zh) | 2023-05-19 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与ret基因改变相关疾病的用途和方法 |
| WO2025256440A1 (zh) * | 2024-06-14 | 2025-12-18 | 四川科伦博泰生物医药股份有限公司 | 含杂环化合物富马酸盐的制备方法 |
| WO2026017002A1 (zh) * | 2024-07-16 | 2026-01-22 | 四川科伦博泰生物医药股份有限公司 | 以杂环化合物为活性成分的药物组合物、其制备方法及用途 |
| GB202410599D0 (en) * | 2024-07-19 | 2024-09-04 | Ellipses Pharma Ltd | Therapeutics useful synergistic combinations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101166734A (zh) * | 2005-02-28 | 2008-04-23 | 日本烟草产业株式会社 | 具有Syk抑制活性的新型的氨基吡啶化合物 |
| BRPI0607062A2 (pt) * | 2005-02-28 | 2009-08-04 | Japan Tobacco Inc | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos |
| WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US20080234267A1 (en) * | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| JP2010208945A (ja) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| CN102812022B (zh) * | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
| JP2013107824A (ja) * | 2010-03-17 | 2013-06-06 | Dainippon Sumitomo Pharma Co Ltd | 新規単環ピリミジン誘導体 |
| WO2012057262A1 (ja) * | 2010-10-28 | 2012-05-03 | 日本新薬株式会社 | ピリジン誘導体及び医薬 |
| WO2012154518A1 (en) * | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| US10202365B2 (en) * | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| TWI704148B (zh) * | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JP6888101B2 (ja) * | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
-
2020
- 2020-02-11 JP JP2021571055A patent/JP7615056B2/ja active Active
- 2020-02-11 MX MX2021009971A patent/MX2021009971A/es unknown
- 2020-02-11 CN CN202311264080.7A patent/CN117327078A/zh active Pending
- 2020-02-11 WO PCT/CN2020/074696 patent/WO2020168939A1/zh not_active Ceased
- 2020-02-11 SG SG11202107848TA patent/SG11202107848TA/en unknown
- 2020-02-11 BR BR112021016299-2A patent/BR112021016299A2/pt unknown
- 2020-02-11 EP EP20760123.8A patent/EP3929198A4/en active Pending
- 2020-02-11 CN CN202311221283.8A patent/CN117263945B/zh active Active
- 2020-02-11 CN CN202080009954.2A patent/CN113316578B/zh active Active
- 2020-02-11 PH PH1/2021/552004A patent/PH12021552004A1/en unknown
- 2020-02-11 IL IL285378A patent/IL285378B2/en unknown
- 2020-02-11 AU AU2020226422A patent/AU2020226422C1/en active Active
- 2020-02-11 CA CA3130245A patent/CA3130245A1/en active Pending
- 2020-02-11 US US17/431,930 patent/US20220144847A1/en active Pending
- 2020-02-11 KR KR1020217022806A patent/KR102977603B1/ko active Active
-
2021
- 2021-08-17 SA SA521430084A patent/SA521430084B1/ar unknown
- 2021-08-18 CL CL2021002205A patent/CL2021002205A1/es unknown
- 2021-08-20 CO CONC2021/0011023A patent/CO2021011023A2/es unknown
-
2024
- 2024-12-27 JP JP2024231551A patent/JP7821259B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020226422A1 (en) | 2021-09-09 |
| IL285378B1 (en) | 2025-07-01 |
| PH12021552004A1 (en) | 2022-09-05 |
| NZ778907A (en) | 2025-05-30 |
| CN113316578A (zh) | 2021-08-27 |
| WO2020168939A1 (zh) | 2020-08-27 |
| CO2021011023A2 (es) | 2021-09-09 |
| AU2020226422C1 (en) | 2026-04-02 |
| JP7615056B2 (ja) | 2025-01-16 |
| JP7821259B2 (ja) | 2026-02-26 |
| KR20210131314A (ko) | 2021-11-02 |
| US20220144847A1 (en) | 2022-05-12 |
| IL285378A (en) | 2021-09-30 |
| CN117327078A (zh) | 2024-01-02 |
| JP2025060928A (ja) | 2025-04-10 |
| SG11202107848TA (en) | 2021-08-30 |
| SA521430084B1 (ar) | 2025-05-01 |
| AU2020226422B2 (en) | 2025-07-31 |
| CL2021002205A1 (es) | 2022-04-22 |
| EP3929198A1 (en) | 2021-12-29 |
| BR112021016299A2 (pt) | 2021-10-13 |
| CN113316578B (zh) | 2023-10-31 |
| JP2022521859A (ja) | 2022-04-12 |
| CN117263945A (zh) | 2023-12-22 |
| CN117263945B (zh) | 2026-08-11 |
| IL285378B2 (en) | 2025-11-01 |
| KR102977603B1 (ko) | 2026-06-12 |
| CA3130245A1 (en) | 2020-08-27 |
| EP3929198A4 (en) | 2022-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
| ECSP18082774A (es) | Derivados aromáticos de sulfonamida | |
| UY37847A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| MX2019015431A (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| CL2018002009A1 (es) | Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. | |
| UY37480A (es) | Nuevos derivados de quinolina | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| CL2020002891A1 (es) | Nuevos derivados de quinolina | |
| CR20190504A (es) | COMPUESTO DE AMIDA (Divisional 2015-0454) | |
| SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| MX2021015853A (es) | Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida. | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| CO2021001849A2 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. | |
| CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). | |
| MX388378B (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| BR112020026507A8 (pt) | Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4 | |
| BR112021018084A8 (pt) | Medicamento e método para tratamento ou prevenção de complicações de diabetes usando o mesmo medicamento | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| MX2019014436A (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa. |